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Abstract
Background: Herbal medicines have been used in cancer treatment, with many exhibiting favorable side effect
and toxicity profiles compared with conventional chemotherapeutic agents. SH003 is a novel extract from Astragalus
membranaceus, Angelica gigas, and Trichosanthes Kirilowii Maximowicz combined at a 1:1:1 ratio that impairs the growth
of breast cancer cells. This study investigates anti-cancer effects of SH003 in prostate cancer cells.
Methods: SH003 extract in 30% ethanol was used to treat the prostate cancer cell lines DU145, LNCaP, and PC-3. Cell
viability was determined by MTT and BrdU incorporation assays. Next, apoptotic cell death was determined by Annexin
V and 7-AAD double staining methods. Western blotting was conducted to measure protein expression levels of
components of cell death and signaling pathways. Intracellular reactive oxygen species (ROS) levels were measured
using H2DCF-DA. Plasmid-mediated ERK2 overexpression in DU145 cells was used to examine the effect of rescuing
ERK2 function. Results were analyzed using the Student’s t-test and P-values < 0.05 were considered to indicate
statistically-significant differences.
Results: Our data demonstrate that SH003 induced apoptosis in DU145 prostate cancer cells by inhibiting ERK
signaling. SH003 induced apoptosis of prostate cancer cells in dose-dependent manner, which was independent of
androgen dependency. SH003 also increased intracellular ROS levels but this is not associated with its pro-apoptotic
effects. SH003 inhibited phosphorylation of Ras/Raf1/MEK/ERK/p90RSK in androgen-independent DU145 cells, but not
androgen-dependent LNCaP and PC-3 cells. Moreover, ERK2 overexpression rescued SH003-induced apoptosis in
DU145 cells.
Conclusions: SH003 induces apoptotic cell death of DU145 prostate cancer cells by inhibiting ERK2-mediated
signaling.
Keywords: SH003, Herbal medicine, Apoptosis, ERK pathway, DU145 human prostate cancer cells, Anticancer effect
Background
Prostate cancer is the second-most common cancer oc-
curring in men in the United States [1]. Furthermore,
the American Cancer Society notes that although the
mortality of prostate cancer patients is low, prostate can-
cer still accounts for a high rate of cancer occurrence
[2]. Therefore, the development of new drugs should aid
prostate cancer patients.
Almost all prostate cancers develop from glandular
cells, and are therefore classified as adenocarcinomas.
Prostate cancer cells are also classified into androgen-
dependent and-independent groups. While apoptosis of
androgen-dependent cells is induced by androgen ablation,
other mechanisms are required to induce apoptosis of
androgen-independent cells [3, 4]. Furthermore, androgen-
independent cells proliferate rapidly and their presence is
associated with a poor prognosis [5, 6]. Therefore, the
development of novel therapeutic strategies to treat an-
drogen-unresponsive prostate cancer cells is required.
Commonly used prostate cancer cell lines include
DU145, PC-3, and LNCaP cells, which have been derived
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from metastatic prostate cancer lesions from brain,
bone, and lymph node tissues, respectively [7]. Because
these cell lines originate from different organs and their
associated tumor microenvironments are disparate, each
cell line has distinct characteristics [8]. DU145 cells are
androgen-insensitive and express prostate-specific anti-
gen. These characteristics are typical of difficult-to-treat
prostate cancer lesions.
The mitogen-activated protein kinases (MAPKs) are a
family of kinases that modulate cell proliferation, survival,
differentiation, and development [9, 10]. MAPK pathways
transduce signals from extracellular stimuli such as growth
factors and mitogens to the nucleus [11–13]. Aberrant sig-
naling of the MAPK ERK is tightly associated with cancer
progression [14, 15]. Moreover, overexpression of ERK
predicts a poor prognosis in many cancers [16, 17]. Thus,
ERK-mediated signaling represents a molecular target
for cancer treatment [18]. Furthermore, many natural
products exert anti-cancer effects through inhibiting
ERK-mediated signaling [7, 8, 19].
Many patients have a growing interest in phytomedicines.
Conventional chemotherapeutic agents can have significant
side effects, and interest in the use of natural herbal medi-
cines in the prevention and/or treatment of many diseases
including cancer has been increasing [20, 21]. SH003 is
an extract from Astragalus membranaceus (Am), Angelica
gigas (Ag), and Trichosanthes Kirilowii Maximowicz (Tk).
The herbal components of SH003 exhibit anti-cancer ef-
fects [19, 22, 23], and suppress breast cancer growth [24].
In the present study, we investigated whether SH003
exerts anti-cancer effects on human prostate cancer cells.
We report that SH003 induces apoptotic cell death in




SH003 was extracted from Am (333 g), Ag (333 g), and
Tk (333 g) at a 1:1:1 ratio, according to the principles of
traditional Korean medicine. Each component under-
went sensory evaluation by Korean Pharmacopoeia stan-
dards. Am and Tk were from China, and Ag was of
Korean origin. These extracts were concentrated under
reduced pressure at ≤ 60 °C and were obtained from
Hanpoong Pharm and Foods Company (Jeonju, Korea)
[10, 24]. Dry powders were dissolved in 30% ethanol and
were prepared as final stock concentrations of 20 mg/mL.
Cell culture and viability assay
DU145 human prostate cancer cells were cultured in
RPMI-1640 medium containing 10% fetal bovine serum
and 1% antibiotic. Cells were maintained in a humidified
atmosphere with 5% CO2 at 37 °C. Cell viability was
measured using the MTT assay (Sigma-Aldrich, USA).
Cells were seeded on 96-well plates and treated with
various concentrations of herbal extract for 72 h. After
treatment, MTT working solution was added and cells
were incubated at 37 °C for a further 2 h. Next, dimethyl
sulfoxide was added to each well to dissolve the forma-
zan crystals. The absorbance of each well was measured
at 570 nm using an ELISA reader (Molecular Devices,
Palo Alto, CA).
Apoptosis analysis by flow cytometry
Apoptotic cell death was determined by flow cytometry
following Annexin V/7-AAD double staining. Cells were
seeded and treated with various concentrations of SH003
for 48 h. After treatment, cells were harvested, resuspended
in binding buffer, and stained with Annexin V and 7-AAD.
Flow cytometry was conducted using a FACSCalibur in-
strument (BD Biosciences, San Jose, CA, USA). Data were
analyzed using CellQuest Pro software (BD Biosciences).
Cell proliferation assay
Cell proliferation was measured by labeling cells with
bromodeoxyuridine (BrdU) and propidium iodide (PI)
prior to flow cytometry. BrdU-positive cells and PI stain-
ing were used to identify cells in S phase and expression
of total DNA [25, 26]. Cells were treated with SH003 for
48 h and labeled with 10 μM BrdU (Sigma-Aldrich) for
1 h before harvesting. Cells were then trypsinized and
fixed in 70% ethanol on ice for 20 min. Next, cells were
incubated with 2 M HCl/0.5% Tween-20/phosphate-
buffered saline (PBS) for 30 min at room temperature.
After washing with 1% bovine serum albumin (BSA) in
PBS, cells were stained with anti-BrdU antibody (1:50;
Santa Cruz, CA, USA) in buffer (0.5% Tween-20/1%
BSA in PBS) for 30 min at room temperature. Cells were
washed and then incubated for 30 min at room
temperature with goat anti-mouse IgG-FITC (1:100;
Santa Cruz). Washed cells were resuspended in PI for
30 min on ice. Cell proliferation was analyzed by FACS-
Calibur using CellQuest Pro software.
Western blot analysis
DU145 cells were lysed in radioimmunoprecipitation
assay buffer (150 mM NaCl, 1% Triton X-100, 1% so-
dium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM
Tris–HCl [pH 7.5], 2 mM ethylenediaminetetraacetic
acid) and 15 μg of protein was separated on 6–12% gels
by sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis Proteins were transferred to polyvinylidene difluoride
membranes and then membranes were blocked in PBS
with 0.1% Tween-20 containing 1% BSA and 1.5% skim
milk for 1 h. After washing, the membranes were
probed with primary antibody at 4 °C overnight, and
then incubated with horseradish peroxidase-conjugated
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secondary antibody for 1 h at room temperature. The
blot was developed using the EZ-western detection kit
(Daeillab Service, Co., Seoul, Korea). Anti-cleaved
caspase-8, −cleaved caspase-3, −PARP, −JNK, −p38, −p-
ERK1/2, −p-SRC (Tyr-416 and Tyr-527), −SRC, −p-
STAT3, −STAT3, −p-PI3K, −PI3K, −p-AKT (Ser-473),
−AKT, −Ras, −p-Raf1 (Ser-259 and Ser-338), −p-MEK1/2,
−p-p90RSK (Ser-380), and -RSK1/RSK2/RSK3 antibodies
were purchased from Cell Signaling Technology (Danvers,
MA, USA). Anti-β-Actin, −p-JNK, −p-p38, −ERK2, and
-Raf1 antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz). The band intensities of specific anti-
bodies were normalized and analyzed by ImageJ (Broken
Symmetry Software, version 1.4.3.67).
Fig. 1 SH003 induces apoptosis in DU145 cells. a DU145 cells were exposed to the indicated concentrations of SH003 for 72 h or treated with
30% ethanol as control, and cell viability was measured by the MTT assay. Experiments were performed three times independently and data are
presented as the means ± SD.*P < 0.05. b Cells were treated with SH003 for 48 h and double-stained with anti-BrdU and propidium iodide (PI). Cell
proliferation was determined using cells stained with BrdU for DNA synthesis and DNA content was detected by PI. The dot blots display BrdU
incorporation (Y-axis) and DNA content (X-axis). c DU145 cells were exposed to SH003 for 48 h and then stained with Annexin V and 7-AAD
before flow cytometry. Data are presented as the means ± SD and experiments were replicated three times. *P < 0.05. d Levels of apoptosis-related
proteins were detected by western blotting with indicated antibodies after treatment with SH003 for 24 h. β-actin was used as a loading control. Black
triangle indicates increasing concentrations of SH003 (50, 250, and 500 μg/mL)
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ROS measurement
Intracellular levels of reactive oxygen species (ROS) were
measured by flow cytometry. First, cells were seeded and
treated with SH003 for 1 h. In parallel with drug treat-
ment for 1 h, cells were stained using 2′-7′-dichlorodi-
hydrofluorescein diacetate (H2DCF-DA) fluorescent dye
to measure ROS production for 1 h at 37 °C. Cells were
harvested, washed with PBS, filtered, and analyzed by
FACSCalibur. N-acetyl-L-cysteine (NAC) was used as ROS
scavenger.
Transfections
Cells were seeded and transfected with pEGEP-C1 or
pEGEP-C1-ERK2 plasmids using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Transfected cells were
used for western blotting and apoptosis analyses.
Statistical analysis
Data are presented as the means ± standard deviation
(SD). Differences between groups were analyzed using a
Student’s t-test. P-values < 0.05 were considered to indi-
cate significant differences.
Results
SH003 induces apoptosis in DU145 prostate cancer cells
We first investigated the effects of SH003 on the viability
of DU145 prostate cancer cells using MTT assays. Cells
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Fig. 2 Effects of intracellular ROS generation on apoptotic cell death of DU145. a Cells were treated with 50, 250, or 500 μg/mL SH003 and
H2DCF-DA dye for 1 h at 37 °C. b Cell were pretreated with 3 mM NAC for 30 min and then treated with 500 μg/mL of SH003. ROS generation in
DU145 cells was measured by flow cytometry. Experiments were repeated three times. *P < 0.05. c Cells were pretreated with 3 mM of NAC for
1 h and then treated with 500 μg/mL SH003 for another 48 h. Apoptosis was detected by flow cytometry and data are presented as the means ± SD.
Experiments were performed in triplicate. *P < 0.05. d Apoptosis-related protein levels were detected by western blotting
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for 72 h. SH003 decreased cell viability in a dose-
dependent manner (Fig. 1a). BrdU incorporation assays
revealed that SH003 reduced the percentage of BrdU-
positive cells (Fig. 1b). These findings indicate that
SH003 reduces DU145 cell viability.
We next treated DU145 cells with SH003 for 48 h
and found that the number of apoptotic cells (Annexin
V+/7-AAD− and Annexin V+/7-AAD+) increased in a
dose-dependent manner (Fig. 1c). Consistently, SH003 in-
duced cleavage of caspase-8, caspase-3, and PARP (Fig. 1d).
These data indicate that SH003 induced apoptotic cell
death in DU145 cells. Likewise, SH003 also induced
apoptosis in both LNCaP and PC-3 cells (Additional
file 1: Figure S1), suggesting that SH003 can induce
apoptosis in multiple prostate cancer cell subtypes.
Intracellular ROS generation is not involved in
SH003-mediated apoptosis
ROS induces apoptotic cell death [27–29], so we next
examined whether treatment with SH003 increased
intracellular ROS levels. SH003 induced ROS production
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1    0.86  0.47   0.57
1    0.88  0.64   0.67
1    1.41  1.3   1.61
1     1.3   0.91  1.14
1    0.93  0.31  0.19
1    0.89  0.64  0.57
1    0.87  0.97   0.64
1    1.21  1.61   1.23
1    0.95  1.38   1.1
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1     1.24  0.99   1.3
1     0.53  0.61   0.72
1    1.06   0.66   0.99
1    0.66   0.78   0.8
Fig. 3 Effects of SH003 on the activation of intracellular signaling pathways and induction of apoptosis by JNK phosphorylation in DU145 cells.
DU145 cells were exposed to 50, 250, or 500 μg/mL SH003 for 15 min and western blotting was used to determine expression levels of
a ERK, JNK, and p38 related MAPK components, b SRC-STAT3 signaling pathway components, or c PI3K-AKT pathway proteins. β-actin served
as the internal control. d Cells were pretreated with 10 μM SP600125 for 30 min and then treated with 500 μg/mL SH003 for 24 h. Levels of
apoptosis-related proteins and p-JNK were measured by western blotting. e Cells were pretreated with 10 μM of SP600125 for 30 min and
then treated with 500 μg/mL SH003 for 48 h before staining with Annexin V and 7-AAD at room temperature in the dark. Levels of apoptosis were
analyzed by flow cytometry. *P < 0.05
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induced increased intracellular ROS levels decreased
when cells were treated with NAC (Fig. 2b). However,
combination treatment with SH003 and NAC increased
apoptosis (Fig. 2c and d), indicating that SH003-
mediated apoptosis did not require intracellular ROS
generation.
SH003-induced JNK phosphorylation is not required for
apoptotic cell death
We next examined the intracellular signaling pathways
induced by SH003. SH003 reduced phosphorylation of both
ERK and p38MAPK, but induced JNK phosphorylation
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1   0.59  0.3  0.13
1   1.68  3.03  6.77
1   0.73  0.53  0.47
1   2.11  3.25  3.01
1   0.6  0.74  1.15
1   1.6  1.27  0.54
1   0.5  0.74  1.05
1  0.87 1.19  1.42
1      0.24   1.6    0.29
1     0.38   0.42    0.46
Fig. 4 SH003 induces apoptotic cell death in DU145 cells via the ERK signaling pathway. a Western blotting of ERK signaling-related protein
expression levels in DU145 cells treated with indicated concentrations of SH003. b Western blotting of ERK2 and PARP levels in DU145 cells
transfected with ERK2-expressing or control vectors and treated with indicated concentration of SH003 for 24 h. c Flow cytometry analysis of
apoptotic cell death of DU145 cells transfected with the ERK2-expressing or control vectors. Results are presented as the means ± SD of three
independent experiments. *P < 0.05 comparison of control vector-transfected cells with ERK2-transfected cells treated with SH003 in late apoptosis,
#P < 0.05 comparison of ERK2-transfected cell with SH003 treatment in early apoptotic cells. d Schematic of the hypothetical system regulated by
SH003. SH003 induces apoptosis in prostate cancer cells and inactivates ERK signaling
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SRC, STAT3, PI3K, or AKT (Fig. 3b and c). While our
previous work found that SH003 inhibits STAT3 in
MDA-MB-231 breast cancer cells [24], this did not occur
in DU145 prostate cancer cells. Therefore, SH003 may in-
hibit the growth of different cancer cells using cell-specific
mechanisms.
Because SH003 activated JNK phosphorylation in DU145
cells, we next investigated whether SH003-mediated apop-
tosis is regulated by JNK signaling. When DU145 cells
were treated with the JNK1/2 inhibitor SP600125 prior to
SH003 treatment, apoptotic cell death was increased
(Fig. 3d and e). These results indicate that SH003-induced
JNK phosphorylation is not associated with SH003-
mediated induction of apoptosis in DU145 cells.
SH003 inhibits ERK phosphorylation to promote
apoptotic cell death
We next examined whether SH003 regulates the ERK
signaling pathway. SH003 reduced phosphorylation of
Raf1, MEK, ERK, and p90RSK and decreased Ras levels
(Fig. 4a). Furthermore, exogenous expression of ERK in
DU145 cells decreased SH003-induced PARP cleavage
(Fig. 4b). Accordingly, ERK overexpression reduced
SH003-mediated apoptosis based on Annexin V/7-AAD
staining (Fig. 4c). These data indicate that SH003 in-
duced apoptotic cell death of DU145 cells by inhibiting
ERK-associated signaling (Fig. 4d). However, SH003 did
not alter the ERK phosphorylation status in LNCaP and
PC-3 cells (Additional file 2: Figure S2). This suggests
that SH003 induced apoptosis by intracellular mecha-
nisms other than ERK signaling in these cells.
Discussion
SH003 is a modified traditional herbal medicine that we
have recently developed and used to inhibit breast can-
cer growth and metastasis [24, 30–32]. Our present
findings demonstrate that SH003 can also cause the
apoptotic cell death of prostate cancer cells. We found
that SH003 induced apoptosis in DU145, LNCaP, and
PC-3 prostate cancer cells. These findings suggest that
the pro-apoptotic effects of SH003 are not restricted to
specific prostate cancer cell types. Taken together with
our recent studies describing SH003-mediated breast
cancer cell death [24, 30, 33], these results suggest that
the anti-cancer effect of SH003 may also not be limited
to cancer types.
SH003 increased intracellular ROS levels in DU145
cells. However, while excessive ROS levels can induce
apoptosis [28, 34], our data reveal that SH003 induces
apoptosis of DU145 cells independently of ROS levels.
Although we still do not know the role of SH003-medi-
ated increased ROS levels in DU145 cells, it is possible
that the levels of ROS present may be insufficient to
directly induce apoptosis. Additionally, SH003-mediated
JNK phosphorylation was also not associated with
SH003-mediated apoptosis of DU145 cells. Therefore,
the precise role of SH003-induced JNK activation remains
to be determined.
Our data show that SH003-mediated inhibition of
ERK phosphorylation is crucial for apoptotic cell death,
with these findings confirmed by rescue experiments.
We have also recently shown that SH003 inhibits VEGFR
phosphorylation in VEGF-stimulated endothelial cells
[32]. Moreover, SH003 also reduces EGFR phosphoryl-
ation in MDA-MB-231 breast cancer cells. Presently, we
found that SH003 inhibits Raf phosphorylation. Inhibition
of EGFR signaling is an effective strategy for prostate
cancer treatment [35–37]. While additional findings
and supportive data are required to better understand
the mechanisms by which SH003 functions, it is pos-
sible that SH003 directly regulates receptor tyrosine
kinase-mediated signaling in cancer. Our future studies
will focus on this issue. Our present findings indicate
that SH003-induced ERK inhibition-mediated apoptosis
is limited to DU145 cells. These data suggest that SH003
may evoke different intracellular signaling mechanisms to
effect its anti-cancer functions.
Conclusions
SH003 causes apoptosis of DU145 prostate cancer cells
by inhibiting ERK signaling. While a more complete un-
derstanding of how SH003 differentially affects different
subsets of prostate cancer cell populations is still required,
this study suggests that SH003 could be beneficial for
treating prostate cancer.
Additional files
Additional file 1: Figure S1. Effects of SH003 on apoptosis in LNCaP
and PC-3 cells. a LNCaP and PC-3 cells were treated to the indicated
concentrations with SH003 for 72 h and with 30% ethanol as control.
Cell viability was measured by the MTT assay. Data represents the mean
SD.*P,< 0.05. b Cells were exposed to SH003 for 48 h. The harvested-cells
were double-stained with Annexin V and 7-AAD for 15 min at RT in the dark.
The apoptotic cells were analyzed by FACSCalibur. Data represents the
mean ± SD. c After treatment with SH003 for 24 h, the apoptosis-related
protein levels were confirmed by western blot. β-actin was used as a
loading control. Black triangle means concentrations of SH003 (50, 250,
500 μg/ml). (PDF 118 kb)
Additional file 2: Figure S2. Regulation of protein expression of SH003
on ERK signaling pathway in LNCaP and PC-3 cells. Cells were treated
with SH003 for 15 min and then detected ERK-related protein expression
levels by western blots. Protein expression levels shown above were
quantified using ImageJ. (PDF 111 kb)
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